Elucid Bioimaging, Inc.

Elucid Bioimaging develops FDA-cleared cardiovascular imaging analytics software specializing in quantitative plaque assessment from coronary CT angiography (CCTA). The company's flagship product, PlaqueIQ™, employs CT Virtual Histology™ technology to characterize arterial plaque composition non-invasively, leveraging algorithms trained and validated against ground-truth histopathology. PlaqueIQ quantifies and classifies plaque morphology into calcified, non-calcified matrix, and lipid-rich necrotic core (LRNC) components, delivering patient-, vessel-, and lesion-level analysis with high correlation to ex vivo histology (r=0.87–0.99 across plaque types). The software integrates into clinical PACS workflows via DICOM-wrapped PDFs and interactive browser-based reports, enabling physicians to assess coronary and carotid atherosclerosis risk and guide medical versus interventional treatment decisions. Elucid holds FDA 510(k) clearance (K183012, December 2018) and has achieved Category I CPT coding and broad CMS reimbursement as of January 2026. The company also develops FFRCT (fractional flow reserve CT) technology under regulatory pathway. Served markets include cardiology, interventional cardiology, radiology, and cardiovascular research. Clinical validation includes partnership with CVPath Institute and peer-reviewed publications in major cardiovascular literature.